Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Boineau

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Circulation. Heart Failure|April 18, 2018
Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure TrialEldrin F Lewis, Brian Claggett, Amil M Shah, et al.
Circulation. Heart Failure|December 22, 2012
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trialSanjiv J Shah, John F Heitner, Nancy K Sweitzer, et al.
American Heart Journal|April 15, 2024
Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2)Ana Navas-Acien, Regina M Santella, Bonnie R Joubert, et al.
Circulation|November 20, 2014
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trialMarc A Pfeffer, Brian Claggett, Susan F Assmann, et al.
American Heart Journal|May 22, 2022
The trial to assess chelation therapy 2 (TACT2): Rationale and designGervasio A Lamas, Kevin J Anstrom, Ana Navas-Acien, et al.
The New England Journal of Medicine|April 11, 2014
Spironolactone for heart failure with preserved ejection fractionBertram Pitt, Marc A Pfeffer, Susan F Assmann, et al.
Circulation|January 29, 2014
Risk stratification for sudden cardiac death: a plan for the futureJeffrey J Goldberger, Anirban Basu, Robin Boineau, et al.
Circulation|September 15, 2010
Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood InstituteThomas Force, Robert O Bonow, Steven R Houser, et al.
JAMA Internal Medicine|March 3, 2025
Multivitamins After Myocardial Infarction in Patients With Diabetes: A Randomized Clinical TrialFrancisco Ujueta, Gervasio A Lamas, Kevin J Anstrom, et al.
Circulation|May 4, 2011
Screening for sudden cardiac death in the young: report from a national heart, lung, and blood institute working groupJonathan R Kaltman, Paul D Thompson, John Lantos, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Circulation. Heart Failure|April 18, 2018
Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure TrialEldrin F Lewis, Brian Claggett, Amil M Shah, et al.
Circulation. Heart Failure|December 22, 2012
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trialSanjiv J Shah, John F Heitner, Nancy K Sweitzer, et al.
American Heart Journal|April 15, 2024
Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2)Ana Navas-Acien, Regina M Santella, Bonnie R Joubert, et al.
Circulation|November 20, 2014
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trialMarc A Pfeffer, Brian Claggett, Susan F Assmann, et al.
American Heart Journal|May 22, 2022
The trial to assess chelation therapy 2 (TACT2): Rationale and designGervasio A Lamas, Kevin J Anstrom, Ana Navas-Acien, et al.
The New England Journal of Medicine|April 11, 2014
Spironolactone for heart failure with preserved ejection fractionBertram Pitt, Marc A Pfeffer, Susan F Assmann, et al.
Circulation|January 29, 2014
Risk stratification for sudden cardiac death: a plan for the futureJeffrey J Goldberger, Anirban Basu, Robin Boineau, et al.
Circulation|September 15, 2010
Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood InstituteThomas Force, Robert O Bonow, Steven R Houser, et al.
JAMA Internal Medicine|March 3, 2025
Multivitamins After Myocardial Infarction in Patients With Diabetes: A Randomized Clinical TrialFrancisco Ujueta, Gervasio A Lamas, Kevin J Anstrom, et al.
Circulation|May 4, 2011
Screening for sudden cardiac death in the young: report from a national heart, lung, and blood institute working groupJonathan R Kaltman, Paul D Thompson, John Lantos, et al.
Pageof 4